Cabaletta Bio
Clinical-stage biotechnology company developing engineered autologous T cell therapies that target B cells for treatment of autoimmune diseases. The organization advances a platform for targeted B-cell ablation using CD19-targeting and antigen-specific receptor approaches, operates multiple Phase 1/2 clinical trials across autoimmune indications, and maintains translational, analytical, and manufacturing capabilities to support autologous cell therapy development.
Industries
Nr. of Employees
medium (51-250)
Cabaletta Bio
Philadelphia, Pennsylvania, United States
Products
Fully human CD19-targeting autologous CAR T cell candidate (4-1BB co-stimulatory domain)
Clinical-stage autologous T cell product candidate engineered to target CD19+ B cells for transient depletion and immune system reset; being evaluated across multiple autoimmune indications.
rese-cel
A fully human, autologous 4-1BB CD19-CAR T cell therapy investigated for the treatment of various autoimmune diseases including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
CABA-201
Investigational CD19-specific chimeric antigen receptor T cell therapy (rese-cel) designed to treat myositis by targeting B cells.
FVIII-CAART
A discovery-stage candidate for Hemophilia A patients who have an anti-Factor VIII immune response, designed to destroy antibodies and B cells that neutralize the FVIII clotting factor.
Fully human CD19-targeting autologous CAR T cell candidate (4-1BB co-stimulatory domain)
Clinical-stage autologous T cell product candidate engineered to target CD19+ B cells for transient depletion and immune system reset; being evaluated across multiple autoimmune indications.
rese-cel
A fully human, autologous 4-1BB CD19-CAR T cell therapy investigated for the treatment of various autoimmune diseases including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
CABA-201
Investigational CD19-specific chimeric antigen receptor T cell therapy (rese-cel) designed to treat myositis by targeting B cells.
FVIII-CAART
A discovery-stage candidate for Hemophilia A patients who have an anti-Factor VIII immune response, designed to destroy antibodies and B cells that neutralize the FVIII clotting factor.
Services
Design and operational execution of Phase 1/2 trials evaluating autologous T cell therapies in multiple autoimmune indications.
Process and analytical development, manufacturing oversight, and integration with automated platforms to produce clinical autologous T cell products.
Correlative science including single-cell profiling, serology, cytokine analysis, and B cell phenotyping to support mechanism-of-action and pharmacodynamic assessments.
Design and operational execution of Phase 1/2 trials evaluating autologous T cell therapies in multiple autoimmune indications.
Process and analytical development, manufacturing oversight, and integration with automated platforms to produce clinical autologous T cell products.
Correlative science including single-cell profiling, serology, cytokine analysis, and B cell phenotyping to support mechanism-of-action and pharmacodynamic assessments.
Expertise Areas
- Autologous CAR T and antigen-specific receptor T cell development
- Clinical trial management for cell therapies (Phase 1/2)
- Translational immunology and biomarker development
- CMC and manufacturing scale-up for autologous cell therapies
Key Technologies
- Autologous CAR T cell therapy
- Antigen-specific chimeric receptor T cells
- CD19-targeted B cell depletion
- 4-1BB co-stimulatory domain-containing constructs
News & Updates
Participation in investor conference (presentation).
Investor presentation and webcast at a healthcare conference in New York.
Scientific presentations including clinical and manufacturing translational data at the American Society of Gene & Cell Therapy annual meeting.
Presentation of clinical data and development updates at the European rheumatology congress.
Press release reporting inducement equity grants under Nasdaq listing rules.
Press release announcing participation in upcoming investor conferences.
Participation in investor conference (presentation).
Investor presentation and webcast at a healthcare conference in New York.
Scientific presentations including clinical and manufacturing translational data at the American Society of Gene & Cell Therapy annual meeting.
Presentation of clinical data and development updates at the European rheumatology congress.
Press release reporting inducement equity grants under Nasdaq listing rules.
Press release announcing participation in upcoming investor conferences.